Latest Pharma and Biotech News
Pharmaceutical
17 July 2026 Swiss pharma giant Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.
Today's issue
Refine search
Pharmaceutical
Last week saw AstraZeneca sign an accord with China’s Dizal Pharmaceutical for rights to the latter’s lung cancer drug Zegfrovy. Biogen released new Phase II data its Alzheimer’s candidate diranersen that raised questions. Celcuity won US Food and Drug Administration (FDA) for its investigational breast cancer drug Revtorpyk and Merck & Co announced FDA approval for its oral PCK9 cholesterol drug Lipfendra. Eli Lilly revealed plans to acquire mental health biotech AtaiBeckley for an upfront $2.8 billion. 19 July 2026
Pharmaceutical
Australia’s CSL Limited subsidiary CSL Seqirus has started shipping influenza vaccines to health care providers in the USA, helping them get prepared for the upcoming flu season, to target the H3N2 subclade K strain that drove last season’s historic surge. 18 July 2026
Biotechnology
Canadian genetic medicines company enGene Therapeutics announced changes to its board of directors as it prepares for potential regulatory milestones and commercial readiness for its investigational gene therapy, detalimogene voraplasmid, if approved. 17 July 2026
Pharmaceutical
The US Food and Drug Administration’s (FDA) approval of Utebzi (tebipenem pivoxil) gives physicians the first oral carbapenem option for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. 17 July 2026
Pharmaceutical
Swiss pharma giant Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 17 July 2026
Pharmaceutical
UK pharma major GSK today provided an update on the CALM-1 and CALM-2 Phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in adults with refractory chronic cough (RCC). RCC is a complex and under-recognised disease with limited treatment options. 17 July 2026
Pharmaceutical
Japan’s largest drugmaker Takeda announced new Phase III data for zasocitinib, its investigational, next-generation, highly selective and potent oral TYK2 inhibitor, zasocitinib, including secondary endpoint data showing consistent, high rates of skin clearance in patients with plaque psoriasis, including in high-impact sites. 17 July 2026
Biotechnology
IPOs are back. The first six months of 2026 have seen a some of the biggest stock
market debuts in biopharma history. With IPOs regularly topping the $200m mark,
the amount of money raised in the first half of the year has eclipsed what the entire
sector managed in the whole of 2025. 17 July 2026
Biotechnology
China’s Kelun-Biotech reported that the Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with Merck & Co’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda (pembrolizumab) has met its primary endpoint of progression free survival (PFS) at a prespecified interim analysis. 17 July 2026
Biotechnology
UK biotech company Mission Therapeutics has agreed to hand its acute kidney injury candidate MTX652 to Australian renal specialist Dimerix in a deal that could bring the Cambridge-based firm up to $292 million, freeing it to concentrate on a central nervous system pipeline led by a Parkinson's disease drug. 17 July 2026
Biotechnology
US biotech Jasper Therapeutics has completed its all-stock acquisition of complement-focused Kira Pharmaceuticals, creating a combined immunology company with a broader biologics pipeline for immune-mediated diseases. 17 July 2026
Biotechnology
Chinese biotech InnoCare Pharma has reported positive top-line Phase II data for its oral TYK2 inhibitor soficitinib (ICP-332) in adults with nonsegmental vitiligo. 17 July 2026
Pharmaceutical
Arrowhead Pharmaceuticals has recently announced that the European Commission has granted marketing authorization for Redemplo (plozasiran), an innovative apolipoprotein C III (apoC-III) inhibitor that is already approved in the USA for the treatment of adults with familial chylomicronemia syndrome (FCS). 17 July 2026
Pharmaceutical
Russia is considering a significant increase public procurements of drugs for the treatment of obesity within the next several years, reports The Pharma Letter’s local correspondent. 17 July 2026
Pharmaceutical
USA-based clinical-stage biotherapeutics firm Rani Therapeutics has agreed a research and development collaboration with Chinese metabolic disease specialist PegBio, aiming to reformulate several of the latter's obesity and metabolic candidates for oral delivery via Rani's RaniPill capsule. 17 July 2026
Pharmaceutical
US biotech company Veradermics saw its shares climb more than a tenth on Wednesday after reporting mid-stage results for a drug it hopes will become the first oral treatment approved by the FDA for female pattern hair loss. 17 July 2026
Biotechnology
China’s Insilico Medicine , a leader in clinical-stage generative AI for drug discovery, has announced a multi-target strategic alliance with Taiwan’s Bora Pharmaceuticals.
. 17 July 2026
Pharmaceutical
Latin American countries need to treat health spending as an investment rather than a cost if they are to expand coverage, strengthen health systems and support broader economic development, according to the Latin American Federation of the Pharmaceutical Industry, FIFARMA. 16 July 2026
Biosimilars
Shilpa Biologicals, part of India’s Shilpa Medicare, has entered into a co-development and supply agreement with Finnish drugmaker Orion Corporation for a nivolumab biosimilar. 16 July 2026
Pharmaceutical
US pharma major Eli Lilly has agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion in one of the largest big pharma moves yet into psychedelic-based mental health medicines. 16 July 2026
All news
Pharmaceutical
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for Orpathys (savolitinib) has been granted conditional approval by the China National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. 2 July 2026
Pharmaceutical
Roche today announced positive results from the Phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS G12C inhibitor. 2 July 2026
Biotechnology
Novartis today announced that the European Commission (EC) has approved Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. 2 July 2026
Biotechnology
Otsuka Pharmaceutical has reported positive top-line results from the Phase III VISIONARY study of Voyxact (sibeprenlimab-szsi) in adults with primary IgA nephropathy (IgAN), providing the confirmatory evidence needed to support a bid for full US approval. 2 July 2026
Pharmaceutical
Regeneron Pharmaceuticals has reported further positive Phase III data for cemdisiran in generalized myasthenia gravis, strengthening the case for the investigational treatment as a potential monotherapy in a competitive and increasingly expensive disease market. 2 July 2026
Pharmaceutical
Can-Fite BioPharma plans to advance namodenoson into a Phase IIb study in combination with chemo after the oral drug met the primary safety endpoint and demonstrated durable survival outcomes in a Phase IIa trial in advanced pancreatic ductal adenocarcinoma. 2 July 2026
Biotechnology
Fosun Wanbang, a wholly-owned subsidiary of China’s Fosun Pharma, has entered into a licensing agreement with Shanghai Junshi Bioscience.
. 2 July 2026
Pharmaceutical
The Pharma Letter’s June M&A coverage showed that biopharma buyers remain prepared to pay heavily for late-stage or strategically useful assets, while also using smaller deals to fill technology and infrastructure gaps. 1 July 2026
Pharmaceutical
France’s Abivax today announced the pricing of its previously announced underwritten public offering of 6,400,000 American Depositary Shares (ADSs) each representing one ordinary share, 0.01 euro nominal value per share of the company, in the USA at an offering price of $125.00 per ADS, raising approximately $800 million (702 million euros). 1 July 2026
Pharmaceutical
US pharma major AbbVie presented new 12-month interim data from the ROSSINI study, supporting the real-world safety and effectiveness of Produodopa (foslevodopa/foscarbidopa) in patients with advanced Parkinson’s disease (PD) at the European Academy of Neurology (EAN) 2026 virtual congress. 1 July 2026
Biotechnology
Hong Kong-listed Chinese biotech METiS TechBio has licensed global rights to its preclinical trispecific T-cell engager MTS-128 to Deerfield-backed Boulevard Bio, in a deal potentially worth more than $1.6 billion plus royalties. 1 July 2026
Pharmaceutical
BridgeBio Pharma today announced that it has entered into an agreement with funds managed by Sixth Street and funds managed by HealthCare Royalty, a business of KKR and, together with Sixth Street, under which the purchasers have invested up to $1 billion in newly issued convertible preferred equity of the company. 1 July 2026
Biotechnology
Swiss biopharmaceutical company Idorsia has appointed Roland Wandeler as chief executive officer, effective October 1, as it looks to build on a recent financial turnaround and accelerate growth across its commercial portfolio and late-stage pipeline. 1 July 2026
Biotechnology
US clinical-stage biotech Beeline Medicines has announced the closing of a $126.3 million Series A extension, bringing its total Series A financing round to $426.3 million. 1 July 2026
Pharmaceutical
UK-based BioPhorum today announced the formation of the Synthetic Molecule Process Innovation Phorum, uniting an ecosystem of 20 leading organizations to urgently address the rapidly accelerating pace of innovation in the small molecule sector. 1 July 2026
Biotechnology
French pharma Ipsen is continuing to expand its product portfolio via M&A deals, today announcing plans to acquire privately-owned Swiss biotech Memo Therapeutics. 1 July 2026
Biotechnology
Telum Therapeutics has raised 18 million euros ($21 million) in a series A financing to advance its lead antimicrobial program for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii, a drug-resistant hospital pathogen with limited treatment options. 1 July 2026
Biotechnology
Swiss contract development and manufacturing group Lonza today announced an expanded strategic collaboration with a leading, unnamed, USA-based biopharmaceutical company. 1 July 2026
Pharmaceutical
AlzeCure Pharma has signed an out-licensing and collaboration agreement with Denmark’s privately held QuantumCell, granting the biotech global rights to its NeuroRestore Alzheimer’s platform, including lead candidate ACD856. 1 July 2026
Pharmaceutical
Abivax has reported additional Phase III data for investigational ulcerative colitis therapy obefazimod, saying the expanded dataset strengthens confidence in the oral medicine's long-term safety profile while demonstrating continued clinical benefit in patients who either failed induction treatment or relapsed during maintenance therapy. 1 July 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze